[HTML][HTML] Role of cytokines and chemokines in non-alcoholic fatty liver disease
V Braunersreuther, GL Viviani, F Mach… - World journal of …, 2012 - ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) includes a variety of histological conditions
(ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are …
(ranging from liver steatosis and steatohepatitis, to fibrosis and hepatocarcinoma) that are …
Adiponectin and lipoprotein metabolism
GA Christou, DN Kiortsis - Obesity reviews, 2013 - Wiley Online Library
Adiponectin is secreted by the adipose tissue and it has been shown to be down‐regulated
in states of insulin resistance and in cardiovascular disease. It has also been found to be …
in states of insulin resistance and in cardiovascular disease. It has also been found to be …
Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis
RATIONALE AND OBJECTIVES: Fatty liver disease is a common clinical entity in hepatology
practice. This study evaluates the prevalence and reproducibility of computed tomography …
practice. This study evaluates the prevalence and reproducibility of computed tomography …
[HTML][HTML] Treating NAFLD in OLETF rats with vigorous-intensity interval exercise training
Background There is increasing use of high intensity, interval type exercise training in the
management of many lifestyle-related diseases. Purpose To test the hypothesis that …
management of many lifestyle-related diseases. Purpose To test the hypothesis that …
Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study
Abstract Background and Aim Non‐alcoholic fatty liver disease (NAFLD) is a multisystem
disease associated with an increased risk of cardiovascular disease (CVD), diabetes, and …
disease associated with an increased risk of cardiovascular disease (CVD), diabetes, and …
A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease
PL Chong, D Laight, RJ Aspinall, A Higginson… - BMC …, 2021 - Springer
Background Non-alcoholic fatty liver disease (NAFLD) is associated with increased
cardiovascular risk irrespective of conventional risk factors. The role of gut-liver interaction is …
cardiovascular risk irrespective of conventional risk factors. The role of gut-liver interaction is …
How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease
MV Machado, J Coutinho, F Carepa… - European journal of …, 2012 - journals.lww.com
Background Adipose tissue contributes to nonalcoholic fatty liver disease (NAFLD), being a
source of fatty acids and cytokines such as leptin and adiponectin, and regulating ghrelin …
source of fatty acids and cytokines such as leptin and adiponectin, and regulating ghrelin …
Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease
Y Ma, G Zhang, Z Kuang, Q Xu, T Ye, X Li… - Frontiers in …, 2022 - frontiersin.org
Empagliflozin (EMPA) therapy has led to improvements in patients with non-alcoholic fatty
liver disease (NAFLD). Sestrin2 is a stress-inducible protein that controls the AMPK-mTOR …
liver disease (NAFLD). Sestrin2 is a stress-inducible protein that controls the AMPK-mTOR …
Hepatic lipase activity is increased in non‐alcoholic fatty liver disease beyond insulin resistance
V Miksztowicz, D Lucero, V Zago… - Diabetes/metabolism …, 2012 - Wiley Online Library
Background and objective Hepatic lipase is a lipolytic enzyme mostly synthesized and
localized at the surface of liver sinusoidal capillaries, which hydrolyses triglycerides and …
localized at the surface of liver sinusoidal capillaries, which hydrolyses triglycerides and …
Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins
D Lucero, V Miksztowicz, G Gualano, C Longo… - Clinica chimica acta, 2017 - Elsevier
Background We evaluated possible changes in VLDLcharacteristics, and metabolic related
factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 …
factors, in MetS-associated NAFLD and accompanying liver fibrosis. Methods We studied 36 …